204
Participants
Start Date
January 30, 2020
Primary Completion Date
January 24, 2025
Study Completion Date
January 24, 2025
BGB-A445
Administered as specified in the treatment arm
tislelizumab
Administered as specified in the treatment arm
National Cheng Kung University Hospital, Tainan City
Auckland City Hospital, Auckland
Blacktown Cancer And Haematology Centre, Blacktown
Peter Maccallum Cancer Centre, Melbourne
Nucleus Network, Melbourne
Monash Health, Clayton
Princess Alexandra Hospital, Brisbane
Pindara Private Hospital, Benowa
Linear Clinical Research, Nedlands
King Chulalongkorn Memorial Hospital (Chulalongkorn University), Bangkok
Ramathibodi Hospital Mahidol University, Bangkok
National Cancer Center (NCC), Goyang-si
Cha Bundang Medical Center, Cha University, Gyeonggido
Seoul National University Bundang Hospital, Seongnam-si
UPMC Hillman Cancer Center (Univ Of Pittsburgh), Pittsburgh
The Catholic University of Korea, St. Vincent's Hospital, Suwon
Srinagarind Hospital (Khon Kaen University), Muang
University of Malaya Medical Centre, Kuala Lumpur
Valkyrie Clinical Trials, Los Angeles
California Cancer Associates for Research & Excellence (cCARE), San Diego
Sarawak General Hospital, Kuching
Affiliated Zhongshan Hospital Of Fudan University, Shanghai
Jinan Central Hospital, Jinan
Linyi Cancer Hospital, Linyi
Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The Second Xiangya Hospital Of Central South University, Changsha
Union Hospital Of Tongji Medical College, Huazhong University Of Science And Technology, Wuhan
Severance Hospital Yonsei University Health System, Seoul
Changhua Christian Hospital, Changhua
Lead Sponsor
BeiGene
INDUSTRY